VCHSX: Profile for VALIC COMPANY I HEALTH SCIENCES

Kris Jenner is a Vice President, Portfolio Manager, and Investment Analyst with T. Rowe Price. He joined the firm in June of 1997 and has five years of previous investment experience. He specializes in the coverage of the biotechnology and domestic pharmaceutical sectors of the health care industry. Kris earned a B.S. (Chemistry), summa cum laude from the University of Illinois, a D. Phil. from Oxford university/England, and a M.D. from the Johns Hopkins School of Medicine.

INVESTMENT INFORMATION

Min Initial Investment:	$0
Min Initial Investment, IRA:	NaN
Min Initial Investment, AIP:	NaN
Min Subsequent Investment:	NaN
Min Subsequent Investment, IRA:	N/A
Min Subsequent Investment, AIP:	N/A

VCHSX can be purchased from brokerages.

FUND SUMMARY

The investment seeks long-term capital growth. The fund normally invests at least 80% of assets in the common stocks of companies engaged in "health sciences", including research, development, production, or distribution of products or services related to health care, medicine, or the life science. It may invest up to 35% of total assets in foreign stocks, which include non-dollar denominated securities traded outside the U.S. The fund is nondiversified.

FUND OPERATIONS

Last Dividend (27-Feb-01):	0.00
Last Cap Gain (22-Dec-08):	0.89
Annual Holdings Turnover	43.00%
Average for Category:	134.64%

FEES & EXPENSES

Expense	VCHSX	Category Avg
Total Expense Ratio:	1.18%	1.68%
Max 12b1 Fee:	%	N/A
Max Front End Sales Load:	%	5.35%
Max Deferred Sales Load:	%	2.88%
3 Yr Expense Projection*:	$ 378	$720
5 Yr Expense Projection*:	$ 654	$1,077
10 Yr Expense Projection*:	$ 1,443	$2,106

* Per $10,000 invested

Add to Portfolio

Set Alert

Email to a Friend

•

Top Performers by Style

•

Morningstar Editorials